Lead Product(s): Eslicarbazepine Acetate
Therapeutic Area: Neurology Product Name: Zebinix
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination February 17, 2021
BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).